Back to search
FDAFDA · Food and drugs·Recall number D-0212-2025

Duloxetine Delayed-Release Capsules USP, 20 mg, packaged in a) 30 Unit Doses (3x10 blister packs) NDC 0904-7043-04 and b) 100 Unit Doses (10x10 blister packs) NDC 0904-7043-61, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA.

Published February 5, 2025 · Recall initiated: January 13, 2025

Summary

FDA records drug Class II recall D-0212-2025, published February 5, 2025 and initiated January 13, 2025. Recalling firm: The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories; Status: Terminated; Reported quantity: a) 6408 boxes and b)1488 boxes; Lot: Lot #: a) N01530, Exp. Date 01/2025; b) N01540, Exp. Date. 01/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
Distributor
Nationwide within the United States
Lot
Lot #: a) N01530, Exp. Date 01/2025; b) N01540, Exp. Date. 01/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine Delayed-Release Capsules USP, 20 mg, packaged in a) 30 Unit Doses (3x10 blister packs) NDC 0904-7043-04 and b) 100 Unit Doses (10x10 blister packs) NDC 0904-7043-61, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA. recalled?

Yes. FDA published recall D-0212-2025 on February 5, 2025. Reported hazard: CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit

What should I do if I have this product?

Voluntary: Firm initiated · Letter